Neurocrine Biosciences (NBIX) EV to EBIT (2011 - 2026)
Neurocrine Biosciences' EV to EBIT was 15.37 in Q3 2026, down 34.4% from 23.41 a year earlier and down 27.0% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EV to EBIT (2011 - 2026) Analysis & Trends
On a trailing twelve-month basis, Neurocrine Biosciences' EV to EBIT was 11.77 through Sep 30, 2026, down 34.5% year-over-year; for FY2025, it was 20.54, down 6.2% from FY2024.
- In earlier years, EV to EBIT was 21.90 in FY2024 (-54.1%), 47.69 in FY2023 (+12.8%), 42.28 in FY2022 (-41.2%) and 71.88 in FY2021 (+43.6%).
- Quarterly EV to EBIT has moved between 15.13 (Q1 2026) and 131.38 (Q2 2022) over five years.
- Compared with a year earlier, EV to EBIT has declined for four straight quarters, with an average decline of 16.0% over the last eight quarters.
- The best year-over-year quarter for EV to EBIT over five years was Q3 2022 (growth of 117.7%); the worst was Q3 2024 (a decline of 63.1%).
- Per Business Quant data, NBIX's EV to EBIT in the three quarters before Q3 2026 was 21.05 (Q2 2026), 15.13 (Q1 2026) and 20.54 (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 15.37 |
| Jun 30, 2026 | 21.05 |
| Mar 31, 2026 | 15.13 |
| Dec 31, 2025 | 20.54 |
| Sep 30, 2025 | 23.41 |
| Jun 30, 2025 | 23.17 |
| Mar 31, 2025 | 20.22 |
| Dec 31, 2024 | 21.90 |
| Sep 30, 2024 | 18.02 |
| Jun 30, 2024 | 23.97 |
| Mar 31, 2024 | 27.27 |
| Dec 31, 2023 | 47.69 |
| Sep 30, 2023 | 48.79 |
| Jun 30, 2023 | 54.63 |
| Mar 31, 2023 | 68.14 |
| Dec 31, 2022 | 42.28 |
| Sep 30, 2022 | 86.07 |
| Jun 30, 2022 | 131.38 |
| Mar 31, 2022 | 111.85 |
| Dec 31, 2021 | 71.88 |
API Access
Neurocrine Biosciences EV to EBIT API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-ebit", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();